Key Takeaways
- Floreo filed a De Novo request, not a 510(k), which would create a new FDA device classification. The De Novo pathway is reserved for novel devices with no legally marketed predicate, meaning an FDA grant would establish FloreoRx as the first predicate for future VR autism therapeutics.
- The pivotal trial hit statistical significance across clinician- and parent-rated measures. Conducted with Cortica across 18 sites over 15 months with 125 patients, CARS-2 showed an LSMean change of -4.5 versus -2.2 in the active VR sham control (p=0.0182) and CFQL-2 family quality-of-life showed a 0.152 between-group difference (p=0.032).
- Effects were largest in the highest-severity subgroup and persisted after treatment ended. Participants in the highest-burden tertile at baseline showed a 72% responder rate versus 30% in the control (p=0.009), and AIM score improvements at the 12-week endpoint were sustained at the 60-day follow-up.
- FDA authorization is the reimbursement unlock ABA has been waiting for. Floreo already holds Tennessee Medicaid coverage (approved September 2025) and an AMA Category III CPT code (0770T, 2023); FDA authorization is the step that opens durable Medicaid and commercial coverage, and Cleveland Clinic added $1 million in follow-on capital on April 17 ahead of a planned Series B.
The distinction between FDA clearance pathways is the one detail most trade coverage of Floreo’s announcement has blurred, and it is the detail that matters most for operators and investors reading the story. FloreoRx is pursuing a De Novo classification request, not a 510(k) clearance. The 510(k) route relies on substantial equivalence to a legally marketed predicate device; it is how EarliPoint Health’s FDA-cleared eye-tracking autism diagnostic aid reached the market in 2022 and then expanded its indication through age 8. The De Novo process exists precisely for devices with no predicate. If the FDA grants the request, Floreo will not be joining an existing class of VR therapeutic devices. It will be creating one.
That regulatory shape has downstream consequences. A successful De Novo grant produces a new product code and a new classification regulation, both of which subsequent VR therapeutic entrants could use as predicates for faster 510(k) submissions. It also positions FloreoRx as what Floreo’s announcement describes as potentially one of the first FDA-authorized therapeutic devices targeting core social communication challenges in autism spectrum disorder. The Breakthrough Device Designation Floreo received in 2023, paired with its admission to the FDA’s Total Product Life Cycle Advisory Program (TAP), is the infrastructure that has moved the company toward this moment.
FloreoRx Pivotal Trial: 125 Patients, 18 Cortica Sites, 15 Months
The trial that supports the submission was designed as a prospective, multi-site randomized controlled trial of FloreoRx within applied behavior analysis autism therapy, compared against an active VR sham control. Conducted with Cortica, a national provider of integrated pediatric autism care, it ran across 18 clinical sites over a 15-month period that spanned both blinded therapy delivery and a crossover phase. Cortica enrolled 125 patients and coordinated more than 150 behavioral technician VR coaches and 15 blinded assessors, a scale Floreo’s announcement describes as among the largest RCTs of a VR-based intervention in children with autism. MCRA served as the CRO, and Highland BioMed provided regulatory support on the De Novo package.
The treatment dose is a detail worth pausing on. Participants received roughly 18 minutes of VR-based FloreoRx use per week over 12 weeks, which totals under four hours of cumulative VR time across the full treatment arc. CEO Vijay Ravindran said in the announcement that three findings stand out from the trial: that Floreo achieved statistically significant results at that dose, that the treatment effect grew with baseline symptom severity, and that improvements continued to strengthen during the 60-day post-treatment follow-up window.
CARS-2, CFQL-2, and AIM: The Clinical Data Behind the De Novo Submission
On the clinician-administered CARS-2, the Floreo group showed an LSMean change of -4.5 compared with -2.2 in the control (p=0.0182). On the caregiver-reported CFQL-2 family quality-of-life measure, the between-group difference reached 0.152 (p=0.032). At clinically interpretable thresholds on the Autism Impact Measure, responder rates in the Floreo group reached 45.6% compared with 23.3% in the VR control. The subgroup finding in the highest-burden tertile was more pronounced: a 72% responder rate against 30% in the control (p=0.009). On functional skill acquisition, 95.1% of participants mastered one or more new skills by the end of treatment, measured against the Assessment of Functional Living Skills.
Two other details in the data deserve attention. First, improvements in AIM scores at the 12-week end of treatment were sustained at 60 days post-treatment, suggesting the intervention produced durable rather than transient effects. Second, participants who started in the VR control arm and then transitioned into Floreo treatment showed improvements consistent with the originally randomized Floreo group, which Floreo’s announcement frames as support for the consistency of the observed effect. No serious adverse events were reported in the study, and observed adverse events were generally mild and transient.
Why FDA Authorization Is the Reimbursement Unlock ABA Has Been Waiting For
For the behavioral health services economy, the FDA submission is less about the device itself than about what FDA authorization would unlock downstream. Floreo has been building the reimbursement rails for years. The company played an important role in securing the Category III CPT code (0770T) that the American Medical Association approved in 2023 for VR use in therapy, though that code is primarily a tracking mechanism. Ravindran has said in prior interviews that FDA clearance is the step that opens state Medicaid coverage and potentially allows school districts accessing Medicaid dollars to secure the full cost of the system. Floreo already secured Tennessee Medicaid coverage in September 2025 through the state’s Department of Disability and Aging Enabling Technology Program, which authorized reimbursement across TennCare’s managed care organizations and 1915(c) Home and Community-Based Services waivers.
Against the broader technology-in-autism-care landscape, the FDA move lands at a specific moment. Trilliant Health’s 2026 Behavioral Health Report found that ABA visit volume has grown 309.2% since the introduction of ABA CPT codes in 2019, a growth curve that has drawn payer and policymaker scrutiny. Pervasive developmental disorders, including autism, drive 376.8 pediatric visits per 1,000, with a 93.0% increase between 2018 and 2024. Providers operating inside that demand curve are actively looking for evidence-based, billable adjunctive therapies that can extend clinical capacity without adding proportional labor cost. A VR therapeutic delivered during ABA sessions at 18 minutes per week fits that profile if the reimbursement pathway comes with it. Acuity has covered how AI and virtual reality are expanding what ABA can do across the broader tech and care models transforming autism and IDD in 2026.
Cleveland Clinic’s $1 Million Follow-On and a Planned Series B
Axios Pro reported on April 17 that Cleveland Clinic has invested an additional $1 million in Floreo, building on the strategic investment it made in April 2024 alongside Floreo’s acquisition of the Cleveland Clinic Innovations-spun-out Autism Eyes diagnostic platform. Ravindran told Axios Pro that Floreo is planning a Series B round during FDA review. The company last raised institutional capital in October 2022, closing a $10 million Series A led by Tenfore Holdings with participation from the Autism Impact Fund, The Disability Opportunity Fund, and Felton Group. A Cleveland Clinic-anchored follow-on at the De Novo filing stage is a meaningful vote of confidence on the regulatory trajectory.
FDA review timelines for De Novo requests vary, and the agency does not comment on submissions under review. If authorized, Floreo intends to position FloreoRx as an adjunct to existing therapeutic approaches for the approximately 3% of U.S. children diagnosed with autism spectrum disorder. The commercial Floreo platform currently on the market for wellness and skills development will remain separate from FloreoRx, which the company emphasizes is an investigational product under FDA review. The arrival of an FDA-authorized therapeutic device with measurable outcomes fits squarely into the accountability era for autism care, where payers are demanding objective measurement and providers are under pressure to demonstrate clinical progress. For behavioral health operators, M&A advisors, and payers, the question is not whether the underlying VR therapeutic category will exist. It is whether FloreoRx becomes the predicate that defines it.
Frequently Asked Questions
What is FloreoRx and what did Floreo announce on April 20, 2026?
FloreoRx is an investigational software-based therapeutic device that uses virtual reality, delivered by behavioral therapists during applied behavior analysis sessions, to help children with autism develop social communication skills. On April 20, 2026, Floreo announced that it had submitted a De Novo classification request to the FDA for FloreoRx. The submission is supported by data from a pivotal randomized controlled trial conducted with Cortica across 18 clinical sites over 15 months. FloreoRx is distinct from the commercial Floreo VR wellness platform, which does not make therapeutic claims.
How is the FDA De Novo pathway different from a 510(k) clearance?
The 510(k) pathway requires a manufacturer to demonstrate substantial equivalence to a legally marketed predicate device. The De Novo pathway exists for novel devices where no predicate exists, and where general or general-plus-special controls can provide reasonable assurance of safety and effectiveness. A successful De Novo grant produces a new product code and classification regulation, which subsequent entrants in the same device category can use as a predicate for future 510(k) submissions. FloreoRx is pursuing De Novo because no FDA-authorized VR therapeutic for autism currently exists to serve as a predicate.
What did the Floreo pivotal trial find?
The trial evaluated FloreoRx against an active VR sham control in children with autism receiving ABA therapy. Clinician-administered CARS-2 evaluations showed an LSMean change of -4.5 for the Floreo group versus -2.2 for the control (p=0.0182). Caregiver-reported CFQL-2 family quality-of-life scores showed a between-group difference of 0.152 (p=0.032). Responder rates on the Autism Impact Measure reached 45.6% in the Floreo group compared with 23.3% in the control, and participants in the highest-burden tertile at baseline showed a 72% responder rate versus 30% (p=0.009). A majority of participants (95.1%) mastered one or more new skills by the end of treatment. No serious adverse events were reported.
How much VR exposure did participants receive, and over what period?
Participants received approximately 18 minutes of FloreoRx VR-based treatment per week over a 12-week course, totaling less than four hours of cumulative VR time across the full treatment arc. The 60-day follow-up assessment showed that AIM-score improvements at the end of treatment were sustained at two months post-treatment. CEO Vijay Ravindran has pointed to the combination of low treatment dose, durability of effect, and stronger performance in higher-severity participants as the three results he considers most significant from the trial.
Who partnered with Floreo on the trial and the regulatory submission?
The pivotal trial was conducted with Cortica Healthcare across 18 clinical sites nationwide. Cortica’s Chief Medical Officer is Dr. Suzanne Goh, and the organization’s integrated whole-child autism care model served as the clinical infrastructure for the study. MCRA served as the contract research organization, and Highland BioMed provided strategic regulatory assistance on the preparation of the De Novo submission. Cortica enrolled 125 patients and coordinated more than 150 behavioral technician VR coaches and 15 blinded assessors over the 15-month trial period.
What would FDA authorization mean for Medicaid and commercial reimbursement?
FDA authorization does not automatically guarantee reimbursement, but it is the step that unlocks most state Medicaid and commercial coverage pathways for a digital therapeutic. Floreo has previously secured state-level Medicaid coverage, including in Tennessee in September 2025 through the Department of Disability and Aging’s Enabling Technology Program, which extends across all three TennCare managed care organizations. Ravindran has said publicly that FDA authorization is the mechanism that would expand those coverage pathways meaningfully. A Category III CPT code (0770T) for VR use in therapy, approved by the AMA in 2023, exists as a tracking code, but durable commercial reimbursement typically follows FDA authorization and coverage-policy updates by individual payers. The broader trend of AI at the front door of behavioral health is accelerating payer appetite for FDA-backed digital therapeutics with measurable outcomes.
How does Floreo fit into the broader technology landscape in autism care?
Floreo sits alongside a small cohort of FDA-regulated autism-focused devices. EarliPoint Health received 510(k) clearance in 2022 for its eye-tracking diagnostic aid and has since expanded its indication to cover children ages 16 months through 95 months. If authorized, FloreoRx would be differentiated in that it targets therapy rather than diagnosis and pursues a De Novo classification rather than a 510(k). The broader context is a behavioral health demand curve in which autism services utilization has grown rapidly, and in which operators are looking for evidence-based adjunctive therapies that can extend clinical capacity under constrained workforce and reimbursement conditions.
